EE151 Cost Minimization Analysis Evaluating Turoctocog ALFA (NOVOEIGHT®) and Product X As Prophylaxis Treatment for Paediatric and Adult Patients with Severe Haemophilia a in China
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.400
https://www.valueinhealthjournal.com/article/S1098-3015(22)00601-5/fulltext
Title :
EE151 Cost Minimization Analysis Evaluating Turoctocog ALFA (NOVOEIGHT®) and Product X As Prophylaxis Treatment for Paediatric and Adult Patients with Severe Haemophilia a in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00601-5&doi=10.1016/j.jval.2022.04.400
First page :
Section Title :
Open access? :
No
Section Order :
10351